Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure

Bumsoo Park
*Henry Ford Health System*

Raghavendra C. Vemulapalli
*Henry Ford Health System*, RVEMULA1@hfhs.org

Amit Gupta
*Henry Ford Health System*, AGUPTA6@hfhs.org

Maria Shreve
*Henry Ford Health System*, mshreve1@hfhs.org

Della A. Rees
*Henry Ford Health System*, DREES1@hfhs.org

Follow this and additional works at: [https://scholarlycommons.henryford.com/familymedicine_articles](https://scholarlycommons.henryford.com/familymedicine_articles)

**Recommended Citation**
Park B, Vemulapalli RC, Gupta A, Shreve ME, and Rees DA. Docetaxel-induced systemic sclerosis with internal organ involvement masquerading as congestive heart failure. Case Reports Immunol 2017; 2017:4249157.

This Article is brought to you for free and open access by the Family Medicine at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Family Medicine Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Case Report

Docetaxel-Induced Systemic Sclerosis with Internal Organ Involvement Masquerading as Congestive Heart Failure

Bumsoo Park, Raghavendra C. Vemulapalli, Amit Gupta, Maria E. Shreve, and Della A. Rees

Department of Family Medicine, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI 48202, USA

Correspondence should be addressed to Bumsoo Park; bpark1@hfhs.org

Received 2 November 2016; Revised 9 January 2017; Accepted 22 January 2017; Published 6 February 2017

1. Introduction

Systemic sclerosis, or scleroderma, is a complex medical disorder characterized by limited or diffuse skin thickening with frequent involvement of internal organs such as lungs, gastrointestinal tract, or kidneys. Docetaxel is a chemotherapeutic agent which has been associated with cutaneous side effects. An uncommon cutaneous side effect of docetaxel is scleroderma-like skin changes that extend from limited to diffuse cutaneous systemic sclerosis. Several case reports have been published regarding the association of docetaxel and systemic sclerosis. However, those reports demonstrated the association between docetaxel and scleroderma-like skin changes without internal organ involvement. Here, we report a case of systemic sclerosis with pulmonary arterial hypertension and a microangiopathic kidney involvement induced by docetaxel chemotherapy. After an exhaustive literature review, this could be the first case of docetaxel-induced systemic sclerosis involving internal organs.

2. Case Report

A 49-year-old African American woman presented with shortness of breath, who was discharged from the other hospital one week earlier with the diagnosis of acute exacerbation of CHF. Patient was given oral furosemide and carvedilol at discharge, however, she admitted to losing her prescription for carvedilol resulting in her not taking it since discharge. She exhibited bilateral leg edema on examination without crackles or jugular venous distention. Brain natriuretic peptide was elevated to 1330 pg/mL. Chest radiograph demonstrated cardiomegaly with minimal interstitial edema. Echocardiography from the other hospital showed an ejection fraction (EF) of 50%, pulmonary arterial pressure (PAP) of 56 mmHg, and normal left ventricular diastolic filling. Recurrent exacerbation of CHF secondary to...
idiopathic pulmonary arterial hypertension (PAH) triggered by medication noncompliance was initially diagnosed, and the patient was started on intravenous furosemide. However, no clinical improvement was noted with no reasonable urine output. The medical team doubted the diagnosis of CHF exacerbation and started to do more thorough history taking and a comprehensive physical examination.

The patient had a history of breast cancer and underwent left lumpectomy followed by 4 cycles of chemotherapy using docetaxel/cyclophosphamide and radiation therapy about a year ago. She was given 134 mg of docetaxel and 1,074 mg of cyclophosphamide on a monthly basis. On repeat examination, she demonstrated diffuse thickening/sclerosis of bilateral hands that crossed metacarpophalangeal joints extending up to bilateral proximal upper extremities (Figure 1). Extensive sclerosis of skin and subcutaneous tissue of anterior chest wall and the left breast were also noted. Patient endorsed that she started to have pain and stiffness of both hands right after she finished the last cycle of chemotherapy. Echocardiography before the chemotherapy showed EF of 55%, PAP of 26 mmHg, and normal left ventricular (LV) diastolic filling. LV size has been normal without change before and after the chemotherapy. Therefore, her estimated systolic PAP has increased by more than 2-fold after the chemotherapy with newly developing skin sclerosis. Docetaxel-related systemic sclerosis was suspected. Serologic test showed positive antinuclear antibody, but negative anti-centromere and anti-Scl-70 antibodies. Pulmonary function test was normal with slightly decreased diffusing capacity. High-resolution computed tomography of the chest did not show interstitial lung disease. Finally, it was noted that she met the 2013 American College of Rheumatology Classification Criteria of Systemic Sclerosis as she demonstrated skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints (score 9) and PAH (score 2). Per the criteria, patients with a total score of ≥9 are classified as having definite systemic sclerosis [2].

We discontinued diuretic treatment and continued on beta-blocker with calcium-channel blocker. Patient's clinical condition improved and was discharged with follow-up appointment with Rheumatology and Pulmonary Hypertension (PH) clinic.

Upon follow-up chart review, the patient is currently following Rheumatology, Pulmonology, and Dermatology but is also on hemodialysis given worsening renal function with following Nephrology. Renal biopsy was performed and it showed thrombotic microangiopathy pattern (classic “onion-peeling” appearance) which is suggestive of scleroderma per pathologic documentation. She was diagnosed with scleroderma renal crisis by Nephrology and was started on captopril. Patient is currently stable with normal blood pressure and stable serum creatinine levels.

3. Discussion

Our case showed newly developed PAH, thrombotic microangiopathy of the kidney with scleroderma renal crisis, and skin sclerosis of bilateral hands definitive of systemic sclerosis, status post docetaxel treatment.

Among side effects of docetaxel, it has been reported that docetaxel can induce a variety of skin toxicities [3]. One of the rare cutaneous side effects of docetaxel is a scleroderma-like change, and there have been more than 10 case reports. Since three cases of limited systemic sclerosis induced by docetaxel were reported at first [4], there have been reports regarding both limited cutaneous systemic sclerosis [5, 6] and diffuse cutaneous systemic sclerosis [7, 8] induced by docetaxel. The exact mechanism by which docetaxel induces skin sclerosis is unclear. Versican is a large chondroitin sulfate proteoglycan expressed by human fibroblasts. It interacts with cells and enables them to proliferate, migrate, adhere, and assemble an extracellular matrix [9]. Hesselstrand et al. suggested that versican may contribute to skin thickening with excess collagen deposits in systemic sclerosis [10]. Okada et al. reported that intense versican deposits were found in the skin after docetaxel administration [11]. Therefore, versican may play a role in pathogenesis of docetaxel-induced systemic sclerosis.

One of the interesting findings in our report is that our patient developed PAH after docetaxel treatment. So far, no cases have been reported associating docetaxel with PAH. It has been hypothesized that PAH in systemic sclerosis occurs as a consequence of progressive remodeling of pulmonary vasculature with inflammation and endothelial injury as common precursors. A recent study revealed that docetaxel facilitates endothelial injury through oxidative stress mechanism [12]. Thus, docetaxel may induce PAH either by oxidative injury to the endothelial cells or by stimulating fibroblast cells as mentioned earlier.

PH can also be developed by LV dysfunction (Group 2 PH), and it is possible that the patient might have had Group 2 PH given decreased EF from 60% to 50%. However, based on the fact that estimated systolic PAP increased by more than 2-fold compared to decrease in EF by 17% and the LV diastolic function remained normal before and after chemotherapy, it is more likely that the patient might have developed primary PAH (Group 1 PH). Another possible consideration is that cyclophosphamide which the patient was given can cause dilated cardiomyopathy, and this condition might have caused Group 2 PH. However, given the fact that LV size remained constantly normal before and after chemotherapy, it is less likely that the patient developed dilated cardiomyopathy after cyclophosphamide treatment.

Figure 1: Diffuse skin thickening and sclerosis of bilateral hands that cross the metacarpophalangeal joint.
It should also be considered that systemic sclerosis might have developed as a manifestation of breast cancer. Joseph et al. have suggested that a tumor antigen can trigger autoimmune response which can develop systemic sclerosis after they found that a certain genetic mutation triggered cellular immunity and cross-reactive humoral immune responses [13]. However, based on the fact that the patient started to have skin thickening after she finished the chemotherapy and she was diagnosed with breast cancer 2 years ago, it is more likely that the patient developed systemic sclerosis secondary to chemotherapy.

Our study has a limitation that the PAH was diagnosed only based on echocardiography, but not confirmed by right heart catheterization (RHC). RHC should be performed to diagnose PAH in systemic sclerosis per 2013 American College of Rheumatology Classification Criteria of Systemic Sclerosis. We deferred RHC while the patient was hospitalized since the patient was too weak and fatigued to tolerate invasive procedures. However, as the patient also demonstrated biopsy-proven microangiopathic kidney involvement which was pertinent to systemic sclerosis, we still believe that the patient developed an internal organ involvement of systemic sclerosis with not only having skin involvement.

We also admit that we initially missed characteristic findings of bilateral hand sclerosis on examination because we focused only on assessing cardiopulmonary status. An observational study showed that 26% of the inpatient sample had diagnosis and treatment changed substantially as a result of the attending physician's physical examination [14]. Therefore, it cannot be overemphasized that a thorough history taking and comprehensive physical examination are essential for medical practice.

4. Conclusion

The association between docetaxel and scleroderma-like skin changes has been well established in the literature. However, we firstly report a case that docetaxel can also cause systemic sclerosis with internal organ involvement that manifested as PAH and microangiopathic kidney disease. Therefore, we may need to consider the possibility of systemic sclerosis and try to look for any skin thickening if a patient develops unexplained PAH or worsening renal function with docetaxel treatment.

Competing Interests

All authors declare no conflict of interests to disclose regarding this study.

References

[1] F. A. Wollheim, "Classification of systemic sclerosis. Visions and reality," Rheumatology, vol. 44, no. 10, pp. 1212–1216, 2005.
[2] F. van den Hoogen, D. Khanna, J. Fransen et al., “2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis & Rheumatism, vol. 65, no. 11, pp. 2737–2747, 2013.
[3] L. Chew and V. S. L. Chuen, “Cutaneous reaction associated with weekly docetaxel administration,” Journal of Oncology Pharmacy Practice, vol. 15, no. 1, pp. 29–34, 2009.
[4] D. F. Battafarano, G. C. Zimmerman, S. A. Older, J. H. Keeling, and H. A. Burris, “Docetaxel (taxotere) associated scleroderma-like changes of the lower extremities: a report of three cases,” Cancer, vol. 76, no. 1, pp. 110–115, 1995.
[5] S. Vignes and B. Lebrun-Vignes, “Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer,” Journal of the European Academy of Dermatology and Venereology, vol. 21, no. 8, pp. 1131–1133, 2007.
[6] S. M. Bouchard, M. R. Mohr, and R. J. Pariser, “Taxane-induced morphea in a patient with CREST syndrome,” Dermatology Reports, vol. 2, no. 1, 2010.
[7] M. G. Cleveland, B. S. Ajai Kumar, and R. Reganti, “Cutaneous fibrosis induced by docetaxel: a case report,” Cancer, vol. 88, no. 5, pp. 1078–1081, 2000.
[8] G. Hassett, P. Harnett, and N. Manolios, “Scleroderma in association with the use of docetaxel (taxotere) for breast cancer,” Clinical and Experimental Rheumatology, vol. 19, no. 2, pp. 197–200, 2001.
[9] T. N. Wight, M. G. Kinsella, S. P. Evanko, S. Potter-Perigo, and M. J. Merrilees, “Versican and the regulation of cell phenotype in disease,” Biochimica et Biophysica Acta—General Subjects, vol. 1840, no. 8, pp. 2441–2451, 2014.
[10] R. Hesselstrand, G. Westergren-Thorsson, A. Scheja, M. Wildt, and A. Åkesson, “The association between changes in skin echogenicity and the fibroblast production of biglycan and versican in systemic sclerosis,” Clinical and Experimental Rheumatology, vol. 20, no. 3, pp. 301–308, 2002.
[11] K. Okada, Y. Endo, Y. Miyachi, Y. Koike, Y. Kuwatsuka, and A. Utani, “Glycosaminoglycan and versican deposits in taxane-induced sclerosis,” British Journal of Dermatology, vol. 173, no. 4, pp. 1054–1058, 2015.
[12] C.-H. Hung, S.-H. Chan, P.-M. Chu, and K.-L. Tsai, “Docetaxel facilitates endothelial dysfunction through oxidative stress via modulation of protein kinase C beta: the protective effects of sotraustaurin,” Toxicological Sciences, vol. 145, no. 1, pp. 59–67, 2015.
[13] C. G. Joseph, E. Darrah, A. A. Shah et al., “Association of the autoimmune disease scleroderma with an immunologic response to cancer,” Science, vol. 343, no. 6167, pp. 152–157, 2014.
[14] B. M. Reilly, “Physical examination in the care of medical inpatients: An Observational Study,” Lancet, vol. 362, no. 9390, pp. 1100–1105, 2003.